Hemostatic Materials Femoral Artery Hemostasis Performance Testing: Standards, Methods, and Applicat

Vascular Closure and Compression Devices

Mechanical closure devices and femoral compression devices are evaluated for deployment reliability, sealing performance, time to hemostasis, patient ambulation time, and access-site complications, in addition to the standard hemostatic performance endpoints.

Sample Preparation Requirements

Typical requirements include sterile final-packaged units from at least three production batches, a defined lot number, sterilization date and expiry date, storage and transport conditions, complete material composition information, and a sufficient sample quantity to cover in vitro screening, biocompatibility testing, and in vivo studies.

Testing Items

Femoral artery hemostasis performance testing can be grouped into four categories: hemostatic efficacy, blood interaction, physicochemical properties, and safety. Core test items include the following.

• Time to hemostasis (TTH): elapsed time from product application until complete cessation of bleeding, verified by sustained observation.
• Total blood loss volume: measured gravimetrically by weighing gauze and collection materials before and after the procedure.
• Rebleeding rate and first-attempt success rate after initial hemostasis confirmation.
• Whole blood clotting time and dynamic clotting index using human or porcine blood.
• Thromboelastography or rotational thromboelastometry parameters, including reaction time, clot formation kinetics, and maximum clot firmness.
• Platelet adhesion and activation, coagulation marker assays, and hemolysis ratio.
• Fluid absorption capacity and absorption speed in saline and anticoagulated whole blood.
• Swelling ratio, dissolution or resorption time, and residual material behavior.
• Tensile strength, burst strength, and folding flexibility for dressings, patches, and films.
• Extractable pH, residual monomers, solvents, heavy metals, and moisture content.
• Biocompatibility endpoints per the ISO 10993 series: cytotoxicity (ISO 10993-5), hemocompatibility (ISO 10993-4), genotoxicity (ISO 10993-3), sensitization (ISO 10993-23), irritation (ISO 10993-10), acute and subacute systemic toxicity (ISO 10993-11), and local implantation effects (ISO 10993-6).
• Sterility, bioburden, and packaging integrity per ISO 11737, ISO 11137, and ISO 11607 where applicable.

Testing Methods

In Vitro Coagulation and Hemocompatibility Assessment

In vitro screening uses fresh human or porcine whole blood, ideally from non-anticoagulated donors or recalcified citrated blood, to compare clotting behavior between the test material and controls. Common assays include the modified whole blood clotting test, plasma recalcification time, thromboelastography or rotational thromboelastometry, platelet adhesion quantification, hemolysis testing, and complement activation markers. These methods, aligned with ISO 10993-4 for blood-contacting devices, provide rapid, reproducible indicators of hemostatic potential before animal testing is initiated.

Physical and Chemical Characterization

Physical testing measures absorption capacity (grams of fluid absorbed per gram of material), absorption speed, swelling behavior, and degradation profile under simulated physiological conditions. Mechanical testing evaluates tensile strength and elongation for film and fabric products, for example following thin-sheet tensile methods such as ASTM D882, and burst strength for sealant and patch products. Chemical characterization includes extractables screening, residual solvent and monomer analysis, elemental impurities, and pH of aqueous extracts.

In Vivo Porcine Femoral Artery Model

The swine femoral artery puncture model is the internationally accepted reference method for evaluating hemostatic performance under realistic arterial pressure and flow conditions, and it is the basis described in ASTM F2902 for assessing the hemostatic effectiveness of topical hemostatic agents. In a typical protocol, the common femoral artery is accessed percutaneously with a 6F to 8F introducer sheath under imaging guidance. Systemic heparin is administered to achieve an activated clotting time of approximately 250 to 300 seconds, simulating the anticoagulated interventional patient. After sheath removal, animals are randomized to receive the test material or a control treatment such as standard gauze with manual compression or a commercially established comparator.

Primary endpoints include time to hemostasis and total blood loss. Secondary endpoints include rebleeding incidence, hematoma size, and vascular outcomes assessed by Doppler ultrasound or angiography at follow-up, such as vessel patency, stenosis, thrombosis, and pseudoaneurysm formation. At study termination, the puncture site is harvested for gross and histopathological evaluation of arterial healing, inflammation, thrombus organization, and residual test material.

Study Design, Quality, and Animal Welfare

In vivo studies should be prospectively designed with randomization, blinded endpoint assessment, justified sample sizes, and pre-defined statistical methods, typically non-inferiority or superiority testing against the control. Studies are conducted under institutional animal ethics approval and in accordance with ISO 10993-2 animal welfare requirements. Reports prepared to good laboratory practice standards are suitable for inclusion in regulatory submissions.

Applications

Femoral artery hemostasis performance testing serves multiple stakeholders across the product lifecycle of hemostatic materials and devices.

• Research and development: screening formulations, optimizing material structure, and selecting the best-performing candidates before clinical translation.
• Regulatory submission: generating efficacy and safety evidence for market approval applications to national medical device regulatory authorities.
• Design verification and validation: demonstrating that a device meets its intended hemostatic performance claims under standardized, clinically relevant conditions.
• Quality control and batch release: verifying consistency of absorption, clotting, and mechanical performance across production lots.
• Comparative benchmarking: evaluating new products against established commercially available hemostatic materials and standard compression techniques.
• Post-market surveillance: investigating performance questions arising from clinical feedback or field complaints.

Clinically, the resulting data benefit interventional cardiology and interventional radiology departments performing transfemoral procedures, emergency departments managing femoral vascular trauma, and prehospital or military settings where rapid hemorrhage control from proximal arterial injuries is critical.

FAQ

Question: Why is the swine femoral artery model the preferred in vivo model?

Answer: Swine coagulation physiology, blood volume, and femoral artery diameter closely resemble those of humans, allowing realistic sheath-based arteriotomy under anticoagulation. The model reproduces clinical access-site bleeding and enables objective measurement of time to hemostasis, blood loss, and vascular healing, which is why it underpins internationally recognized hemostatic effectiveness test methods such as ASTM F2902.

Question: Which standards govern this type of testing?

Answer: Efficacy testing references ASTM F2902 for topical hemostatic agents; safety testing references the ISO 10993 series (or the equivalent GB/T 16886 series) for biocompatibility, including ISO 10993-4 for blood interaction; sterilization and packaging reference ISO 11137, ISO 11737, and ISO 11607 as applicable.

Question: Why is heparin used in the animal model?

Answer: Most transfemoral procedures are performed under systemic anticoagulation. Inducing heparinization to a target activated clotting time of roughly 250 to 300 seconds stresses the hemostatic material under clinically realistic, adverse conditions and prevents the study from overestimating performance in easy, non-anticoagulated bleeding scenarios.

Question: How is successful hemostasis defined during testing?

Answer: Hemostasis is generally defined as the complete absence of bleeding from the puncture site, sustained for a pre-specified observation period, commonly three minutes, followed by monitoring for rebleeding during the immediate recovery window and the longer follow-up period.

Question: How many samples or animals are required?

Answer: In vitro tests typically require at least three production batches with a minimum of five replicates per batch. In vivo studies commonly use six to ten animals per group, with the final number determined by a statistical power calculation based on expected differences in time to hemostasis and blood loss.

Question: What is a typical project timeline?

Answer: In vitro and physicochemical testing usually requires two to six weeks depending on the test matrix. Biocompatibility studies range from several weeks to several months, and in vivo femoral artery efficacy studies, including ethics approval, animal scheduling, dosing, follow-up, histopathology, and reporting, generally require two to four months.